Working… Menu
Trial record 39 of 61 for:    "Lung Disease" | "Iloprost"

Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00439543
Recruitment Status : Unknown
Verified February 2007 by Interstitial Lung Disease Study Group, Korea.
Recruitment status was:  Not yet recruiting
First Posted : February 23, 2007
Last Update Posted : February 23, 2007
Information provided by:
Interstitial Lung Disease Study Group, Korea

Brief Summary:
Idiopathic pulmonary fibrosis(IPF) is chronic progressive fibrosing lung disease of unknown cause. There is no effective therapy yet for this disease and the mean survival in most reports is about 3 years after the diagnosis. Because of the stiff fibrosis of the lung, pulmonary hypertension is the late complication of IPF and its development heralds a very poor outcome of the patients. For the primary pulmonary hypertension, recently the effective drugs have been available. However, there is no study about the efficacy of these drugs in the patients with pulmonary hypertension secondary to pulmnary fibrosis, and the aim of this trial is to study the safty and efficacy of "Iloprost," one of the safe and effective drugs in primary pulmonary hypertension.

Condition or disease Intervention/treatment Phase
Pulmonary Fibrosis Pulmonary Hypertension Drug: Iloprost inhalation Phase 2 Phase 3

Detailed Description:
  • Prospective open labeled observational study
  • Subjects: About 15 patients with secondary pulmonary hypertension due to IPF or pulmonary fibrosis associated with collagen vascular diseases.
  • Method: 3 month trial of inhaled iloprost. Check the safty and measure the pulmonary arterial pressure by right heart catheterization, exercise capacity by 6 minute walking test, echocardiography, and quality of life questionnaires before and after the trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 15 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Inhaled Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis
Study Start Date : March 2007
Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Iloprost

Primary Outcome Measures :
  1. Safety
  2. Pulmonary arterial pressure
  3. Exercise capacity (6 minute walking test)

Secondary Outcome Measures :
  1. 6 minute walking test: Min. oxygen saturation.
  2. NYHA class,
  3. Quality of life (St. George Respiratory questionnaires)
  4. Pulmonary vascular resistance, cardiac output.
  5. Increment of pulmonary arterial pressure after the exercise
  6. 6) Pulmonary function test

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of idiopathic pulmonary fibrosis or fibrotic NSIP according to American Thoracic Society and European Respiratory Society guidelines by biopsy and diagnosis of pulmonary fibrosis associated with connective tissue disease.
  • Mean pulmonary artery pressure over 30mmHg.
  • NYHA functional class II to IV

Exclusion Criteria:

  • Suffering lung diseases other than pulmonary fibrosis (COPD, Pulmonary Thromboendarterectomy ).
  • Administration of prostanoids, bosentan, beta- blocker or phosphodiesterase5 inhibitor.
  • Dosage adjustment of calcium channel blockers within 6 weeks.
  • Resting pulmonary capillary wedge pressure over 15mmHg.
  • Bleeding tendency.
  • Bilirubin level above 3mg/dl or creatinine clearance level below 30ml/min.
  • Unstable angina pectoris, myocardial infarction or severe arrhythmia within 6 months.
  • Cerebrovascular accident within 6 months.
  • Present lung infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00439543

Layout table for location contacts
Contact: Dong Soon Kim, MD 822-3010-3132
Contact: Sook Hee Jung, RN 8211-9858-9228

Layout table for location information
Korea, Republic of
Pulmonary Medicine, Asan Medical Center, Ulsan University Not yet recruiting
Seoul, Korea, Republic of, 138-736
Principal Investigator: Dong Soon Kim, MD         
Sponsors and Collaborators
Interstitial Lung Disease Study Group, Korea
Layout table for investigator information
Principal Investigator: Dong Soon Kim, MD Asan Medical Center, Ulsan University, Seoul, Korea, Republic of

Layout table for additonal information Identifier: NCT00439543     History of Changes
Other Study ID Numbers: TILOPF
First Posted: February 23, 2007    Key Record Dates
Last Update Posted: February 23, 2007
Last Verified: February 2007
Keywords provided by Interstitial Lung Disease Study Group, Korea:
Pulmonary fibrosis
pulmonary hypertension
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Hypertension, Pulmonary
Pulmonary Fibrosis
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Respiratory Tract Diseases
Platelet Aggregation Inhibitors
Vasodilator Agents